Please login to the form below

Not currently logged in
Email:
Password:

lorcaserin

This page shows the latest lorcaserin news and features for those working in and with pharma, biotech and healthcare.

Eisai takes control of weight loss drug Belviq from Arena

Eisai takes control of weight loss drug Belviq from Arena

The move comes after the launch of a new once-daily formulation of lorcaserin called Belviq XR in the US, replacing the current twice-a-day version. ... However, the bulk ($25m) of the latter comes only if sales of lorcaserin exceed $250m in a calendar

Latest news

More from news
Approximately 4 fully matching, plus 39 partially matching documents found.

Latest appointments

  • Anthony Zook resigns as Vivus CEO Anthony Zook resigns as Vivus CEO

    This coup was led by investment group First Manhattan Co, which had attempted to replace the entire board of Vivus after Qsymia fell behind rival obesity drug Belviq (lorcaserin) from Arena

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Genetic Digital

We help healthcare, pharma & medical device organisations use web and mobile technologies to effectively connect patients and healthcare professionals....

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics